P. Geisser

发表

Effects of Oral Supplementation with Iron (III) Hydroxide Polymaltose Complex on the Hematological Profile of Adolescents with Varying Iron Status

R. Chandra, P. Devaki, P. Geisser, 2008, Arzneimittel-Forschung (Drug Research).

The Pharmacokinetics and Pharmacodynamics of Iron Preparations

P. Geisser, Susanna Burckhardt, Peter Geisser, 2011, Pharmaceutics.

Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay

K. Schwarz, P. Geisser, F. Funk, 2011 .

Interactions between Iron(III)-hydroxide Polymaltose Complex and Commonly Used Drugs

P. Geisser, F. Funk, Susanna Burckhardt-Herold, 2007, Arzneimittelforschung.

Why Different Iron(III)-oxyhydroxide Complexes have Different PK/PDCharacteristics and Specific Reactivities

P. Geisser, 2016 .

Use of intravenous iron supplementation in chronic kidney disease: an update.

I. Macdougall, P. Geisser, 2013, Iranian journal of kidney diseases.

Structure/histotoxicity relationship of parenteral iron preparations.

P. Geisser, M. Baer, E. Schaub, 1992, Arzneimittel-Forschung.

Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress

R. Crichton, P. Geisser, H. Mcardle, 2003, Biometals.

Oral supplementation with ferrous sulfate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation

J. Salonen, T. Tuomainen, R. Salonen, 1999 .

Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes.

P. Geisser, A. Müller, 1987, Arzneimittel-Forschung.

Effect of Oral Supplementation with Iron (III)-hydroxide Polymaltose Complex on the Immunological Profile of Adolescents with Varying Iron Status

P. Devaki, P. Geisser, Pallaki Baby Devaki, 2007, Arzneimittelforschung.

Safety and Efficacy of Iron(III)-hydroxide Polymaltose Complex

P. Geisser, 2007, Arzneimittelforschung.

The pharmacology and safety profile of ferric carboxymaltose (Ferinject ® ): structure/reactivity relationships of iron preparations

P. Geisser, 2009 .

Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers.

P. Geisser, H. Derendorf, T. Salmonson, 1996, Arzneimittel-Forschung.

Effect of Oral Aluminium Hydroxide on Iron Absorption from Iron(III)-hydroxide Polymaltose Complex in Patients with Iron Deficiency Anemia

P. Geisser, J. H. Potgieter, M. A. Potgieter, 2011 .

Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia / a single-centre randomized controlled isotope study.

P. Geisser, J. H. Potgieter, M. A. Potgieter, 2011, Arzneimittel-Forschung.

Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years experience.

P. Geisser, 2007, Arzneimittel-Forschung.

Iron Therapy and Oxidative Stress

P. Geisser, 1997, Metal-based drugs.

Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia

P. Geisser, J. Banké-Bochita, 2010, Arzneimittelforschung.

Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder

P. Geisser, V. Rumyantsev, 2010, Arzneimittelforschung.

The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose

P. Geisser, P. Ryle, F. Funk, 2010, Arzneimittelforschung.

PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.

P. Geisser, E. Philipp, 2010, Clinical nephrology.

In vitro studies on interactions of iron salts and complexes with food-stuffs and medicaments.

P. Geisser, 1990, Arzneimittel-Forschung.

Effects of Oral Iron(III) Hydroxide Polymaltose Complex Supplementation on Hemoglobin Increase, Cognitive Function, Affective Behavior and Scholastic Performance of Adolescents with Varying Iron Status

R. Chandra, P. Devaki, P. Geisser, 2009, Arzneimittelforschung.